Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
By J. Coe, P. Brooks, Michael G. Vetelino, Michael C. Wirtz, E. Arnold, Jianhua Huang, S. Sands, Thomas I. Davis, L. Lebel, C. Fox and 11 more. 2005
867 citations recorded by the source corpus.
Subfields: Molecular Biology, Organic Chemistry
View Paper: https://www.semanticscholar.org/paper/95480dd2d64786d3e6237c5e598ef95e025b0834
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
Citations in the corpus
- Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling (2011, background): “For example, the drug varenicline, which is used in the treatment of nicotine addiction, targets nicotinic receptors on VTA DA neurons (Coe et al., 2005).”
- Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study (2006, background): “Varenicline is highly selective for the 4 2 nicotinic acetylcholine receptor, which is responsible for mediating the reinforcing properties of nicotine in the brain.(5) As a partial agonist with”